iwCLL 2019 | Real-world evidence of venetoclax vs ibrutinib vs idelalisib

Anthony Mato

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, highlights the first real-world evidence of venetoclax vs ibrutinib vs idelalsib in chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  
Similar topics